Aurobindo Pharma hits 52-week high despite 12% decline in PAT in Q4; here's why In the January to March quarter this year, the company's revenues stood at ₹6,472.9 crore, up 11.4% as against ₹5,809.3 crore in the same period last year. By fortuneindia.com
